Clinical Trials

Melanoma, Cutaneous Malignant

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Melanoma, Skin Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

281 enrolled 44 charts

Phase 2/3 Active not recruiting

Melanoma, Neoplasms

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

420 enrolled

Uveal Melanoma, Melanoma

NCT03993379 2025-12-26

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Phase 2 Terminated

3 enrolled 7 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms, Recurrence

NCT04196452 2025-11-20

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active not recruiting

10 enrolled

Phase 1/2 Active not recruiting

Melanoma

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

35 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Completed

100 enrolled

Melanoma

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

67 enrolled

Uveal Melanoma

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

135 enrolled

Melanoma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

110 enrolled 27 charts

DermatologicHead & NeckThoracic

Melanoma

NCT03645928 2025-06-19

LN-144

Phase 2 Recruiting

245 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

41 enrolled 15 charts

Melanoma, Neoplasm Metastasis

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Phase 3 Completed

945 enrolled 19 charts

906 enrolled 16 charts 2 FDA

Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

Melanoma

NCT05909995 2025-02-18

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

DermatologicGastrointestinalGenitourinary

8 enrolled

Turcot syndrome, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

156 enrolled 11 charts

Melanoma

NCT04121676 2025-01-13

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

91 enrolled

Melanoma

NCT02275416 2024-12-16

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

12 enrolled

Melanoma

NCT03153085 2024-12-09

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

28 enrolled

Melanoma

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

11 enrolled

Melanoma

NCT03752398 2024-07-05

DUET-3

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

198 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01740297 2024-05-14

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

217 enrolled 27 charts

Melanoma

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

16 enrolled 14 charts

Melanoma

NCT01621490 2024-04-23

PD-1

170 enrolled 34 charts

Melanoma

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

22 enrolled 14 charts

Melanoma

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02658890 2023-08-28

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

627 enrolled 59 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03408587 2023-05-06

CLEVER

11 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Uveal Melanoma, Coxsackievirus Infections, Virus Diseases

NCT02054520 2023-04-18

Immunotherapy Study for Patients With Stage IV Melanoma

Phase 2 Terminated

47 enrolled 16 charts

Melanoma

NCT04311710 2023-02-24

CheckMate 76U

DermatologicGastrointestinalGenitourinaryThoracic

21 enrolled

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT05714371 2023-02-06

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Completed

618 enrolled

Melanoma

NCT02307149 2023-01-17

MITCI

50 enrolled

Melanoma

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3 Terminated

481 enrolled 22 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies